A Review of Potential Therapeutic Strategies for COVID-19

Viruses. 2022 Oct 25;14(11):2346. doi: 10.3390/v14112346.

Abstract

Coronavirus disease 2019 is a rather heterogeneous disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The ongoing pandemic is a global threat with increasing death tolls worldwide. SARS-CoV-2 belongs to lineage B β-CoV, a subgroup of Sarbecovirus. These enveloped, large, positive-sense single-stranded RNA viruses are easily spread among individuals, mainly via the respiratory system and droplets. Although the disease has been gradually controlled in many countries, once social restrictions are relaxed the virus may rebound, leading to a more severe and uncontrollable situation again, as occurred in Shanghai, China, in 2022. The current global health threat calls for the urgent development of effective therapeutic options for the treatment and prevention of SARS-CoV-2 infection. This systematic overview of possible SARS-CoV-2 therapeutic strategies from 2019 to 2022 indicates three potential targets: virus entry, virus replication, and the immune system. The information provided in this review will aid the development of more potent and specific antiviral compounds.

Keywords: COVID-19; SARS-CoV-2; coronavirus; pathogenesis; therapeutic strategies.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / therapeutic use
  • COVID-19* / therapy
  • China
  • Humans
  • Pandemics / prevention & control
  • SARS-CoV-2

Substances

  • Antiviral Agents

Grants and funding

This research was funded by the Shanghai Agriculture Applied Technology Development Program, China, grant number X20210302, and the National Natural Science Foundation of China, grant number 31972178.